Cargando…

Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone

BACKGROUND: In thyroid-stimulating-hormone (TSH)-based newborn congenital hypothyroidism (CH) screening programs, the optimal screening-TSH cutoff level is critical to ensuring that true cases of CH are not missed. Screening-TSH results can also be used to predict the likelihood of CH and guide appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Saleh, David S., Lawrence, Sarah, Geraghty, Michael T., Gallego, Patricia H., McAssey, Karen, Wherrett, Diane K., Chakraborty, Pranesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735969/
https://www.ncbi.nlm.nih.gov/pubmed/26839208
http://dx.doi.org/10.1186/s12887-016-0559-0
_version_ 1782413181183852544
author Saleh, David S.
Lawrence, Sarah
Geraghty, Michael T.
Gallego, Patricia H.
McAssey, Karen
Wherrett, Diane K.
Chakraborty, Pranesh
author_facet Saleh, David S.
Lawrence, Sarah
Geraghty, Michael T.
Gallego, Patricia H.
McAssey, Karen
Wherrett, Diane K.
Chakraborty, Pranesh
author_sort Saleh, David S.
collection PubMed
description BACKGROUND: In thyroid-stimulating-hormone (TSH)-based newborn congenital hypothyroidism (CH) screening programs, the optimal screening-TSH cutoff level is critical to ensuring that true cases of CH are not missed. Screening-TSH results can also be used to predict the likelihood of CH and guide appropriate clinical management. The purpose of this study is to evaluate the predictive value of various screening-TSH levels in predicting a diagnosis of CH in the Ontario Newborn Screening Program (ONSP). METHODS: The initial screening and follow-up data of 444,744 full term infants born in Ontario, Canada from April 1, 2006 to March 31, 2010 were analyzed. Confirmed CH cases were based on local endocrinologists’ report and initiation of thyroxine treatment. RESULTS: There were a total of 541 positive screening tests (~1/822 live births) of which 296 were true positives (~1:1,500 live births). Subjects were further subdivided based on screening-TSH and positive predictive values (PPV) were calculated. Twenty four percent in the 17–19.9 mIU/L range were true positives. In the 17–30 mIU/L range, 29 % were true positives with a significantly higher PPV for those sampled after (43 %) rather than before (25 %) 28 h of age (p < 0.02). Seventy three percent of neonates with an initial screening-TSH of ≥ 30 mIU/L and 97 % of those with ≥ 40 mIU/L were later confirmed to have CH. CONCLUSIONS: Infants with modestly elevated screening positive TSH levels between 17 and 19.9 mIU/L have a significant risk (24 %) of having CH. The very high frequency of true positives in term newborns with initial TSH values ≥ 30mIU/L suggests that this group should be referred directly to a pediatric endocrinologist in an effort to expedite further assessment and treatment. Screen positives with a modestly elevated TSH values (17-19.9 mIU/L) need to be examined in more detail with extended follow-up data to determine if they have transient or permanent CH.
format Online
Article
Text
id pubmed-4735969
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47359692016-02-03 Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone Saleh, David S. Lawrence, Sarah Geraghty, Michael T. Gallego, Patricia H. McAssey, Karen Wherrett, Diane K. Chakraborty, Pranesh BMC Pediatr Research Article BACKGROUND: In thyroid-stimulating-hormone (TSH)-based newborn congenital hypothyroidism (CH) screening programs, the optimal screening-TSH cutoff level is critical to ensuring that true cases of CH are not missed. Screening-TSH results can also be used to predict the likelihood of CH and guide appropriate clinical management. The purpose of this study is to evaluate the predictive value of various screening-TSH levels in predicting a diagnosis of CH in the Ontario Newborn Screening Program (ONSP). METHODS: The initial screening and follow-up data of 444,744 full term infants born in Ontario, Canada from April 1, 2006 to March 31, 2010 were analyzed. Confirmed CH cases were based on local endocrinologists’ report and initiation of thyroxine treatment. RESULTS: There were a total of 541 positive screening tests (~1/822 live births) of which 296 were true positives (~1:1,500 live births). Subjects were further subdivided based on screening-TSH and positive predictive values (PPV) were calculated. Twenty four percent in the 17–19.9 mIU/L range were true positives. In the 17–30 mIU/L range, 29 % were true positives with a significantly higher PPV for those sampled after (43 %) rather than before (25 %) 28 h of age (p < 0.02). Seventy three percent of neonates with an initial screening-TSH of ≥ 30 mIU/L and 97 % of those with ≥ 40 mIU/L were later confirmed to have CH. CONCLUSIONS: Infants with modestly elevated screening positive TSH levels between 17 and 19.9 mIU/L have a significant risk (24 %) of having CH. The very high frequency of true positives in term newborns with initial TSH values ≥ 30mIU/L suggests that this group should be referred directly to a pediatric endocrinologist in an effort to expedite further assessment and treatment. Screen positives with a modestly elevated TSH values (17-19.9 mIU/L) need to be examined in more detail with extended follow-up data to determine if they have transient or permanent CH. BioMed Central 2016-02-02 /pmc/articles/PMC4735969/ /pubmed/26839208 http://dx.doi.org/10.1186/s12887-016-0559-0 Text en © Saleh et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Saleh, David S.
Lawrence, Sarah
Geraghty, Michael T.
Gallego, Patricia H.
McAssey, Karen
Wherrett, Diane K.
Chakraborty, Pranesh
Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
title Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
title_full Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
title_fullStr Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
title_full_unstemmed Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
title_short Prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
title_sort prediction of congenital hypothyroidism based on initial screening thyroid-stimulating-hormone
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735969/
https://www.ncbi.nlm.nih.gov/pubmed/26839208
http://dx.doi.org/10.1186/s12887-016-0559-0
work_keys_str_mv AT salehdavids predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone
AT lawrencesarah predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone
AT geraghtymichaelt predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone
AT gallegopatriciah predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone
AT mcasseykaren predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone
AT wherrettdianek predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone
AT chakrabortypranesh predictionofcongenitalhypothyroidismbasedoninitialscreeningthyroidstimulatinghormone